Qilu Pharmaceutical’s Generic Pomalidomide Wins NMPA Nod for Multiple Myeloma Treatment
Qilu Pharmaceutical, a leading pharmaceutical company based in China, has received approval from the National...
Qilu Pharmaceutical
Qilu Pharmaceutical Achieves First Approval for Generic Bendamustine in China
The National Medical Products Administration (NMPA) has granted marketing approval to Qilu Pharmaceutical’s generic bendamustine,...
Qilu Pharmaceutical Gets NMPA Green Light for Generic Romiplostim for ITP Treatment
The National Medical Products Administration (NMPA) in China has granted marketing approval to Qilu Pharmaceutical...
China Anti-Cancer Association Forms Consortium for Standardizing Cancer Research Ethics Reviews
The medical ethics professional committee of the China Anti-Cancer Association (CACA) has announced the formation...
Sichuan Kelun-Biotech Secures NMPA Nod for Generic Lynparza Equivalent
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a Chinese pharmaceutical company, has announced that it...
Qilu Pharmaceutical’s Iruplinalkib Gains Additional Indication Approval in China for ALK-Positive NSCLC
The National Medical Products Administration (NMPA) website has indicated that Qilu Pharmaceutical’s Category 1 drug,...
Suzhou Ribo Life Science Strikes Deal with Qilu Pharmaceutical for PCSK9 siRNA Drug
Suzhou Ribo Life Science Co., Ltd, a specialist in small interfering RNA (siRNA) drugs based...
Jiangxi Jemincare Group Secures NMPA Approval for Generic Ibrance Capsules
Jiangxi Jemincare Group, a Chinese pharmaceutical company, has announced that it has received market approval...
Qilu Pharmaceutical Unveils Promising Data for QL1706 in Cervical Cancer Treatment at ESMO 2023
China’s Qilu Pharmaceutical showcased compelling data for its combination drug QL1706 (iparomlimab and tuvonralimab) as...
Qilu Pharmaceutical Presents Promising Data for QL1706 and QL1209 at ESMO 2023
China-based Qilu Pharmaceutical has announced the presentation of clinical data for two of its pipeline...
US FDA Approves Additional Shipments of Qilu Pharmaceutical’s Cisplatin to Address Shortage
The US Food and Drug Administration (FDA) is maintaining its reliance on China-based Qilu Pharmaceutical...
Qilu Pharmaceutical’s Iruplinalkib Receives NMPA Approval for ALK+ NSCLC Treatment
China-based Qilu Pharmaceutical has announced that its Category 1 chemical drug, iruplinalkib, an ALK inhibitor,...
Qilu Pharmaceutical Gains Temporary FDA Approval to Import Cisplatin Amid US Shortage
Qilu Pharmaceutical, a China-based firm, has benefited from the effects of drug shortages in the...
Qilu Pharmaceutical Launches First Generic Iressa in the US Market
China-based Qilu Pharmaceutical has announced the market launch of its generic version of AstraZeneca’s (AZ,...
Luye Pharma’s BA1102 Biosimilar to Xgeva Accepted for CDE Review
China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing for its...
Qilu Pharmaceutical’s QLS12004 Gains Tacit Clinical Trial Approval
The Center for Drug Evaluation (CDE) website indicates that China-based Qilu Pharmaceutical’s Category 1 chemical...
Qilu Pharmaceutical’s Biosimilar Lucentis Accepted for Review by China’s CDE
China-based Qilu Pharmaceutical has announced that its market approval filing for a biosimilar version of...
Henlius’ Hanbeitai Gains NMPA Approval for Expanded Indications
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that the National Medical Products Administration (NMPA)...
Qilu Pharmaceutical’s QL1604 Plus Chemotherapy Shows Promise in Phase II Study
China-based Qilu Pharmaceutical announced that the results of the Phase II study assessing its QL1604...
Qilu Pharma’s QL1706 Shows Promise in Phase II Cervical Cancer Study
China-based Qilu Pharmaceutical has published the latest results from a Phase II clinical study for...